KMT2C and myeloid leukemia: Accordingly, KMT2C has been reported as a tumor repressor frequently altered in several types of cancers, including myeloid leukemia, colorectal cancer, medulloblastoma, pancreatic ductal adenocarcinoma, glioblastoma, and lung adenocarcinoma.28